Patten & Patten’s Regeneron Pharmaceuticals REGN Stock Holding History

Patten & Patten’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-480	Closed	-$304K	–	332
2025 Q1	$304K	Buy	480 +14	+3%	+$9.63K	0.02%	266
2024 Q4	$332K	Sell	466 -6	-1%	-$5.04K	0.02%	253
2024 Q3	$496K	Hold	472	–	–	0.03%	218
2024 Q2	$496K	Hold	472	–	–	0.03%	216
2024 Q1	$454K	Buy	472 +6	+1%	+$5.71K	0.03%	224
2023 Q4	$409K	Hold	466	–	–	0.03%	215
2023 Q3	$383K	Hold	466	–	–	0.03%	210
2023 Q2	$335K	Hold	466	–	–	0.03%	225
2023 Q1	$383K	Buy	466 +6	+1%	+$4.53K	0.03%	207
2022 Q4	$332K	Hold	460	–	–	0.03%	217
2022 Q3	$317K	Sell	460 -5	-1%	-$3.15K	0.03%	221
2022 Q2	$275K	Hold	465	–	–	0.02%	239
2022 Q1	$325K	Hold	465	–	–	0.02%	238
2021 Q4	$294K	Hold	465	–	–	0.02%	244
2021 Q3	$281K	Hold	465	–	–	0.02%	245
2021 Q2	$260K	Hold	465	–	–	0.02%	253
2021 Q1	$220K	Hold	465	–	–	0.02%	259
2020 Q4	$225K	Hold	465	–	–	0.02%	240
2020 Q3	$260K	Hold	465	–	–	0.03%	217
2020 Q2	$290K	Hold	465	–	–	0.03%	205
2020 Q1	$227K	Buy	+465	New	+$192K	0.03%	211

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Patten & Patten's REGN Position: Q2 2025 in Review

Patten & Patten sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 480 shares — an estimated $304K sold.

Patten & Patten first reported a position in REGN in Q1 2020 and held it in 21 quarters. The position peaked at $496K in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Patten & Patten reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Patten & Patten sold 480 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $304K.
Patten & Patten first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 21 quarters.
Patten & Patten's Regeneron Pharmaceuticals position peaked at $496K in Q3 2024.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Patten & Patten's 13F filing for Q2 2025, filed 28 Jul 2025.